| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/QAD.0B013E32833B61BA |
| P698 | PubMed publication ID | 20549847 |
| P2093 | author name string | Jean-Paul Viard | |
| Laurent Hocqueloux | |||
| Thierry Prazuck | |||
| Alain Lafeuillade | |||
| Véronique Avettand-Fenoel | |||
| Christine Rouzioux | |||
| Bernard Cardon | |||
| P433 | issue | 10 | |
| P304 | page(s) | 1598-1601 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection | |
| P478 | volume | 24 |
| Q38754318 | "We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry |
| Q38165451 | A cure for AIDS: a matter of timing? |
| Q27344720 | A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model |
| Q41368445 | A novel non-integrative single-cycle chimeric HIV lentivector DNA vaccine |
| Q34379777 | Absence of detectable HIV-1 viremia after treatment cessation in an infant |
| Q90051570 | Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection |
| Q36509575 | Acute HIV-1 infection in the Southeastern United States: a cohort study |
| Q26767476 | Animal Models for HIV Cure Research |
| Q42234163 | Are infants unique in their ability to be "functionally cured" of HIV-1? |
| Q38067646 | Attacking the HIV reservoir from the immune and viral perspective |
| Q37273652 | Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs |
| Q40250340 | Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy |
| Q35831895 | Broadening of Virus-Specific CD8+ T-Cell Responses Is Indicative of Residual Viral Replication in Aviremic SIV Controllers |
| Q52430698 | CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile? |
| Q26865388 | Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? |
| Q38794293 | Cell and gene therapy strategies to eradicate HIV reservoirs |
| Q37354047 | Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy |
| Q37992718 | Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies |
| Q41928841 | Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells |
| Q26998898 | Developing Combined HIV Vaccine Strategies for a Functional Cure |
| Q38032363 | Developing strategies for HIV-1 eradication |
| Q35036284 | Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy |
| Q40458484 | Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants. |
| Q33869222 | Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors |
| Q28742727 | Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption |
| Q42208838 | Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. |
| Q37993454 | Eliminating the HIV reservoir |
| Q41603198 | Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress) on the course of progressive feline leukemia virus infection |
| Q34869927 | Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication |
| Q34567084 | Finding a cure for HIV: will it ever be achievable? |
| Q39357415 | Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. |
| Q47151081 | HIV as a Cause of Immune Activation and Immunosenescence |
| Q58085173 | HIV control: Is getting there the same as staying there? |
| Q34410446 | HIV cure research: advances and prospects |
| Q37771138 | HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals |
| Q36121883 | HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? |
| Q34350410 | HIV-1 DNA predicts disease progression and post-treatment virological control |
| Q38204866 | HIV-1 latency: an update of molecular mechanisms and therapeutic strategies |
| Q90340957 | HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers |
| Q36976156 | HIV-1 transcription and latency: an update |
| Q34403835 | How a single patient influenced HIV research--15-year follow-up |
| Q37149147 | How to best measure HIV reservoirs? |
| Q95724430 | Human Immunodeficiency Virus Type 1 DNA Decay Dynamics With Early, Long-term Virologic Control of Perinatal Infection |
| Q64087572 | Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice |
| Q30362489 | Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? |
| Q40151311 | Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection |
| Q47110966 | Increasing the Clinical Potential and Applications of Anti-HIV Antibodies |
| Q33611645 | Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy |
| Q35072975 | Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents |
| Q39542838 | Inhibition of Feline leukemia virus replication by the integrase inhibitor Raltegravir |
| Q35795271 | Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells |
| Q37109010 | Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. |
| Q38800533 | Kill: boosting HIV-specific immune responses |
| Q92511404 | Learning From the Exceptions: HIV Remission in Post-treatment Controllers |
| Q37724091 | Lessons learned from HIV vaccine clinical efficacy trials |
| Q39395758 | Lessons to be Learned from Natural Control of HIV - Future Directions, Therapeutic, and Preventive Implications |
| Q37002564 | Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation |
| Q90705114 | Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy |
| Q36263353 | No evidence of posttreatment control after early initiation of antiretroviral therapy |
| Q42043737 | Nonlinear observer output-feedback MPC treatment scheduling for HIV. |
| Q36274030 | Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection. |
| Q35888710 | Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control |
| Q38701493 | Post-Treatment Controllers: Role in HIV "Cure" Research |
| Q34629153 | Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study |
| Q26828445 | Preventing HIV infection: pre-exposure and postexposure prophylaxis |
| Q40051712 | Primary HIV Infection: Clinical Presentation, Testing, and Treatment |
| Q39425108 | Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
| Q36164175 | Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal |
| Q89929283 | Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription |
| Q34869426 | Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens |
| Q36626743 | Structural brain alterations can be detected early in HIV infection |
| Q35862206 | Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes |
| Q48505361 | The B-Cell Follicle in HIV Infection: Barrier to a Cure |
| Q35829282 | The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency |
| Q33586581 | The detection and management of early HIV infection: a clinical and public health emergency |
| Q64092083 | The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study |
| Q36692642 | The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment |
| Q41630590 | Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection |
| Q38936786 | Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications |
| Q38626469 | Toward a cure for HIV--Seeking effective therapeutic vaccine strategies |
| Q34640562 | Towards an HIV cure: a global scientific strategy |
| Q26830063 | Very early combination antiretroviral therapy in infants: prospects for cure |
| Q37582477 | Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. |
| Q90634406 | Virtual memory CD8+ T cells restrain the viral reservoir in HIV-1-infected patients with antiretroviral therapy through derepressing KIR-mediated inhibition |
| Q45874441 | Wake me up before you go: A strategy to reduce the latent HIV reservoir |
| Q38082905 | Will it be possible to live without antiretroviral therapy? |
Search more.